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Abstract 
Background: New diagnostic tools to detect reliably and rapidly asymptomatic and low‑density malaria infections 
are needed as their treatment could interrupt transmission. Isothermal amplification techniques are being explored 
for field diagnosis of malaria. In this study, a novel molecular tool (loop‑mediated isothermal amplification—LAMP) 
targeting the apicoplast genome of Plasmodium falciparum was evaluated for the detection of asymptomatic malaria‑
infected individuals in a rural setting in The Gambia.
Methods: A blood was collected from 341 subjects (median age 9 years, range 1–68 years) screened for malaria. 
On site, a rapid diagnostic test (RDT, SD Bioline Malaria Antigen P.f ) was performed, thick blood films (TBF) slides for 
microscopy were prepared and dry blood spots (DBS) were collected on Whatman® 903 Specimen collection paper. 
The TBF and DBS were transported to the field laboratory where microscopy and LAMP testing were performed. The 
latter was done on DNA extracted from the DBS using a crude (methanol/heating) extraction method. A laboratory‑
based PCR amplification was done on all the samples using DNA extracted with the Qiagen kit and its results were 
taken as reference for all the other tests.
Results: Plasmodium falciparum malaria prevalence was 37 % (127/341) as detected by LAMP, 30 % (104/341) by 
microscopy and 37 % (126/341) by RDT. Compared to the reference PCR method, sensitivity was 92 % for LAMP, 78 % 
for microscopy, and 76 % for RDT; specificity was 97 % for LAMP, 99 % for microscopy, and 88 % for RDT. Area under 
the receiver operating characteristic (ROC) curve in comparison with the reference standard was 0.94 for LAMP, 0.88 
for microscopy and 0.81 for RDT. Turn‑around time for the entire LAMP assay was approximately 3 h and 30 min for an 
average of 27 ± 9.5 samples collected per day, compared to a minimum of 10 samples an hour per operator by RDT 
and over 8 h by microscopy.
Conclusion: The LAMP assay could produce reliable results the same day of the screening. It could detect a higher 
proportion of low density malaria infections than the other methods tested and may be used for large campaigns of 
systematic screening and treatment.
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Background
Malaria control programmes aiming at decreasing 
local transmission and achieving pre-elimination status 
require proper detection of Plasmodium parasites in the 
peripheral blood, both in febrile patients and asympto-
matic carriers [1]. Asymptomatic carriers, representing 
the human reservoir contributing to the transmission of 
the parasites, generally have much lower parasite densi-
ties compared to symptomatic individuals, at detection 
thresholds (<200 parasites/μL) below which the standard 
diagnostic tools such as microscopy and rapid diagnos-
tic tests (RDTs) become less reliable [2, 3]. For malaria 
elimination efforts to have a better chance of success, it 
is crucial to identify as many malaria-infected carriers 
as possible in order to treat them and possibly interrupt 
transmission. Therefore, the ideal diagnostic tool to sup-
port malaria elimination efforts should have high sensi-
tivity to detect most if not all infected individuals [1].
Molecular methods, such as polymerase chain reac-
tion (PCR), reliably detect low-grade and asymptomatic 
infections from different sample types, including dried 
blood spots (DBS) [4, 5]. However, it is difficult to use 
PCR in field settings because of the equipment and infra-
structure required [6]. New molecular diagnostic tools 
such as loop-mediated isothermal amplification (LAMP) 
have been developed to facilitate rapid target amplifica-
tion through single-temperature incubation, thus reduc-
ing the facility and equipment requirement compared to 
PCR-based methods [7]. LAMP has a potential for use in 
point-of-care (POC) diagnosis of malaria and is already 
being tested in clinical and field settings [8–13].
The development and validation of a novel LAMP 
assay targeting the apicoplast genome of Plasmodium 
falciparum has previously been reported and it showed 
comparable sensitivity and specificity, when tested with 
archived DNA samples, as compared to standard PCR 
method targeting the 18srRNA locus [14]. The objective 
of this study was to evaluate the diagnostic performance 
(sensitivity, specificity and predictive values) and opera-
tional characteristics (turn-around time and ease of use) 
of this novel LAMP assay in a field setting. Results of the 
LAMP assay were compared with those obtained using a 
standard laboratory-based PCR assay.
Methods
Study area and participants
This study was carried out as part of the screening stage 
of an ongoing trial in the eastern part of The Gambia, as 
published elsewhere [15]. Briefly, individuals from the 
study villages around the Basse field station of the Medi-
cal Research Council (MRC) Unit in The Gambia were 
screened between October and December 2014. Verbal 
consent was obtained prior to screening, after a careful 
explanation of the information sheet in the local lan-
guage. All individuals with a fever (body temperature 
≥37.5 °C) were excluded. Ethical clearance was obtained 
from the Gambian Government/MRC Joint Ethics Com-
mittee in The Gambia (approval number: SCC1321 and 
L2014.55).
Sample collection and processing
From a single finger prick, blood samples were col-
lected for RDT (SD Bioline Malaria Antigen P.f, HRP 2, 
Ref: 05FK50), thick blood film and dried blood spots—
DBS (Whatman® 903 Specimen collection paper LOT 
6833909/82). The RDTs were read immediately in the 
field while the DBS and microscopy slides were taken to 
the field station at the end of each day for further pro-
cessing. Slides from RDT positive individuals were 
stained and read immediately upon arrival in the labora-
tory at the field station, according to the study protocols 
of the main trial; those from RDT negative individuals 
were stained the same day but read later for this study. 
Thick blood films were stained with 10  % Giemsa for 
10 min and examined under 1000-fold magnification by 
trained microscopists. Asexual and sexual parasite den-
sity was determined by counting the number of parasites 
per 500 white blood cell (WBC) and parasite density 
was estimated by assuming a mean WBC count of 8000/
μL. All slides were double read and a third microscopist 
resolved all discrepancies.
About a quarter of the DBS samples were processed 
in the field station for LAMP, to determine the turn-
around time, while the rest were analyzed later with the 
same methods. DNA was extracted from the DBS using 
a crude methanol and heating extraction method, imme-
diately followed by the LAMP assay. In addition, DNA 
was also extracted from the same DBS samples using a 
QIAamp DNA mini kit (Qiagen GmbH, Hilden, Ger-
many) and used in a laboratory-based PCR assay that was 
taken as the reference method.
DNA extraction for the LAMP assay
Two 3-mm discs of the DBS were punched for each 
sample into a 96-well Round-Well Block (Qiagen) using 
a 96-well plate plan having the corresponding sample 
screening and identification numbers. A hundred and 
fifty µl of methanol were added to each well and incu-
bated at room temperature for 10 min. The methanol was 
removed and the punched discs dried at room tempera-
ture for approximately 45 min before adding 75 µL of dis-
tilled water. The punched discs were mashed using a new 
pipette tip for each well and the Round-Well Block was 
heated in a water bath at 95 °C for 10 min. The superna-
tant was then transferred to a fresh 96-well plate and 3 µL 
of this from each sample was used for the LAMP assay.
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LAMP assay
The final amplification reaction mixture (25  µL) was 
carried out as previously described [14] and contained 
1.6  µM each of the inner primers FIP and BIP, 0.2  µM 
each of the outer primers F3 and B3c, 0.8 µM each of the 
loop primers LPF and LPB, 1× Isothermal Amplification 
Buffer, 1 Unit of Bst 2.0 WarmStart™ DNA polymerase 
(New England Biolabs), 1.0 mM of each dNTPs, 1.0 mM 
MgCl2, and 3  µL of DNA sample. Known positive and 
negative controls were included in each run. The reac-
tion was performed at 65  °C for 60 min in a water bath 
and the end product was determined and verified visu-
ally, after addition of SYBR Green I, (naked eye) for color 
change by two blinded operators (Fig. 1).
Reference PCR assay
A laboratory-based PCR amplification was done for all 
the samples using DNA extracted with the Qiagen kit, 
according to protocols published by Snounou et  al. for 
both pan genus and species-specific amplification [16]. 
End product of the PCR amplification was visualized and 
double-scored with ethidium bromide-stained agarose 
gel electrophoresis.
Sample size calculation and data analysis
Sample size was calculated using G*Power version 3.1 
[17]. A total number of 317 samples were required at 
95  % power, 5  % precision, an effect size of 0.25, and 5 
degree of freedom (df ). The performance characteristics 
of the LAMP assay as well as that of microscopy and RDT 
were calculated using the standard PCR assay as the ref-
erence method. Cohen’s kappa (κ coefficient) was also 
calculated to assess the degree of agreement between the 
results from the different tests. Comparison of the area 
under the receiver operating characteristic (ROC) curves 
in a paired design was used to assess the relative accu-
racy of each of the tests. Precision of the estimates was 
determined by calculating 95 % confidence interval (CI) 
(rounded up to the nearest whole number) for each test 
statistic. Statistical analysis was performed with Stata 13 
(StataCorp, College Station, TX, USA).
Results
During the study period, 528 samples were collected, 
with a mean of 27 ± 9.5 individuals screened daily. This 
analysis includes 341 samples for which the results for all 
diagnostic tests performed are available. The median age 
of the individuals screened was 9 years, ranging from 1 to 
68 years; there were more females (200/341; 59 %) than 
males (141/341; 41  %), and most study subjects (78  %) 
were less than 15 years old (Table 1). Malaria prevalence 
by microscopy was 30  % (104/341), and more than half 
(59  %) had parasite densities ≤200 parasites/μL. Preva-
lence as determined by RDT (126/341; 37 %) and LAMP 
(127/341; 37 %) did not differ. There were more discrep-
ancies between tests at parasite densities <200 parasites/
μL.
Diagnostic performance characteristics
LAMP had a sensitivity of 92 %, a specificity of 97 %, and 
positive predictive value (PPV) and negative predictive 
value (NPV) of 95 %. Microscopy had a sensitivity of 78 %, 
a specificity of 99 %, a PPV of 98 % and NPV of 88 %. Sen-
sitivity, specificity, PPV and NPV for RDT were 76, 88, 79 
and 86 %, respectively. The sensitivity of LAMP was sig-
nificantly higher than those observed by either micros-
copy or RDT (exact McNemar significance probability 
<0.0001); κ coefficient was 0.9 for LAMP, 0.8 for micros-
copy and 0.6 for RDT (Table  2). Area under the ROC 
curve for the LAMP assay was 0.94 while that of micros-
copy and RDT were 0.88 and 0.82, respectively (Fig. 2).
Fig. 1 Visualization of LAMP reaction in a 96‑well plate format show‑
ing colour differences between positive and negative samples
Table 1 Age groups, gender (%) and parasite density of individuals screened
Age group  
(years)
Male Female Total Median parasite 
density (range)
<5 38 (11 %) 54 (16 %) 92 (27 %) 192 (16–9120)
5–14 81 (24 %) 94 (28 %) 175 (52 %) 64 (16–41,280)
≥15 22 (6 %) 52 (15 %) 74 (21 %) 64 (16–65,600)
Total 141 (41 %) 200 (59 %) 341
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Operational characteristics
It took approximately three and half hours each day to 
process samples for the LAMP assay, which is similar to 
a minimum of 10 samples an hour, per operator by RDT 
in comparison with over 8 h in total for the same num-
ber of samples by microscopy. The time required for the 
drying and incubation steps of the crude DNA extraction 
method, together with the total run-time of the LAMP 
assay represented the largest amount of time used in 
the LAMP test, from the time the samples arrived at the 
facility to the results (Table  3). All the incubation steps 
were done either at room temperature or in a water bath 
so no extra equipment was needed. The LAMP assay was 
high throughput and there was perfect agreement of vis-
ual scoring of the results by naked eye between the two 
independent readers.
Discussion
This study shows the feasibility of deploying LAMP 
testing in a field setting using a novel assay developed 
in-house, with diagnostic performance characteris-
tics >90  % when compared with a laboratory-based 
reference PCR method. Previous work comparing the 
LAMP assay with a nested PCR assay using archived 
DNA samples also showed similar results [14]. The 
diagnostic performance of the LAMP assay was also 
similar to that of a commercial LAMP testing kit used 
for detection of asymptomatic malaria parasite car-
riers in Zanzibar, in comparison with RDT and real-
time PCR [13]. Although a comprehensive cost analysis 
was not done in this study, it is expected that in-house 
developed assays would be cheaper than commercial 
kits [18].
The relatively high malaria prevalence is not surprising 
as the sample collection was carried out during the peak 
of the malaria season, in the eastern part of The Gambia, 
where transmission is still relatively high. Previous stud-
ies carried out in the same region have reported malaria 
prevalence determined by molecular methods ranging 
from 14 to 26 %, while this was much lower by micros-
copy [19, 20].
Table 2 Comparison of all the tests against the reference PCR method
Sn sensitivity, Sp specificity, κ Kappa coefficient, PPV positive predictive value, NPV negative predictive value
PCR +ve PCR −ve Total
LAMP +ve 120 7 127 Sn = 91.6 % (95 % CI 85.5–95.7); Sp = 96.7 % (95 % CI 93.3–98.7)
LAMP −ve 11 203 214 PPV = 94.5 % (95 % CI 89.1–97.8); NPV = 94.9 % (95 % CI 91.1–97.4)
κ = 0.91 (95 % CI 0.84‑0.94)
Mx +ve 102 2 104 Sn = 77.9 % (95 % CI 70.1–84.7); Sp = 99.1 % (95 % CI 96.6–99.9)
Mx −ve 29 208 237 PPV = 98.1 % (95 % CI 93.2–99.8); NPV = 87.8 % (95 % CI 82.9–91.7)
κ = 0.80 (95 % CI 0.73‑0.87)
RDT +ve 100 26 126 Sn = 76.3 % (95 % CI 68.1–83.3); Sp = 87.6 % (95 % CI 82.4–91.8)
RDT −ve 31 184 215 PPV = 79.4 % (95 % CI 71.3–86.1); NPV = 85.6 % (95 % CI 80.2–90.1)
κ = 0.64 (95 % CI 0.56‑0.73)
Total 131 210 341
Fig. 2 AUC ROC curve comparison against the reference PCR 
method. Analysis was done using STATA 13 (StataCorp, College Sta‑
tion, TX, USA). mx microscopy, RDT rapid diagnostic test, lamp loop‑
mediated isothermal amplification
Table 3 Processing and  turn-around-time of  the LAMP 
assay for  the number of  samples collected daily (mean 
of 27 ± 9.5)
Process Time used (h)
Punching of DBS samples including decontamination  
after each sample
1
DNA extraction 1.25
LAMP assay and end point determination 1.25
Turn‑around‑time 3.5
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Although all individuals with fever were excluded 
during the screening stage, information on recent his-
tory of fever or malaria infection was not obtained and 
this may explain the higher prevalence and low agree-
ment observed with RDT, which detects circulating his-
tidine-rich protein II (HRP 2). Malaria indicator surveys 
(MISs) carried out in four countries (Kenya, Senegal, 
Zambia, and Mozambique), reported that prevalence 
determined by RDT was higher than by microscopy. 
Possibly, recently treated infections and persistent cir-
culating antigen (up to 6 weeks after infection clearance, 
in the absence of an ongoing infection) [21, 22] may be 
responsible for the high rate of false positives observed 
with the HRP-2 based RDT. Though the prevalence 
determined by RDT was similar to that by LAMP, the 
former had a higher number of false positives, suggest-
ing that carrying out systematic screening with RDT 
followed by treatment of those tested positives would 
unnecessarily treat an important proportion of individ-
uals while others with asymptomatic infections would 
go undetected.
Processing the samples in a 96-well plate format with 
the LAMP assay was easy to perform and would reduce 
both processing and handling time considerably, com-
pared to processing smaller batches in individual tubes. 
When comparing this with other formats for end point 
determination of the amplified products, such as aga-
rose gel electrophoresis, visualization of color change by 
naked eye was an easier and faster method, reducing post 
amplification manipulations. Overall, it would be much 
easier to train staff to use and interpret the results with 
the LAMP assay than with standard PCR.
Conclusion
With a shorter turn-around-time and high through-
put processing, LAMP results would be available much 
faster than by microscopy and more reliably than with 
RDT, supporting the use of this diagnostic test for mass 
screening and treatment (MSAT) or focused screen-
ing and treatment (FSAT) campaigns. The apicoplast 
genome that this novel LAMP assays targets is unique 
to the parasite, thus ensuring high specificity. There 
have been recent improvements in the use of LAMP for 
field diagnosis, which includes the use of lyophilized or 
freeze-dried reagents and quick one-step DNA extrac-
tion methods or use of direct blood. Although molecular 
methods have only recently been recommended for sur-
veillance or parasite detection in low-endemic regions, 
as the move for global malaria elimination continues, 
simplified molecular tools such as LAMP will most likely 
become the favoured option for diagnosis of asympto-
matic malaria infections.
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